Evidence map›Paper›PMID 41799213›Full record

ReviewTheranostics2026

Panoramic description of ROS-based nanotechnology for osteomyelitis therapy: Challenges, opportunities, and prospects.

Wenqiao Wang, Xiaoying Kong, Jinsheng Shi, Ting Wang

Abstract readReview
In one paragraph

Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wenqiao WangDepartment of Spine Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266700, China.
Xiaoying KongInstitute of Regenerative Medicine and Laboratory Technology Innovation, Qingdao University, Qingdao 266071, China.
Jinsheng ShiQingdao Key Lab of Common Diseases, University of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao 266071, China.
Ting WangDepartment of Spine Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266700, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteomyelitis, an inflammatory disease of bone and bone marrow caused by infectious microorganisms, has long been a major clinical challenge due to the lack of consistently effective treatment strategies. Conventional therapeutic approaches, such as antibiotic therapy and surgical debridement, are frequently associated with the development of antibiotic resistance and a high risk of disease recurrence, thereby complicating long-term clinical management. In recent years, reactive oxygen species (ROS)-based nanotechnology has emerged as a promising therapeutic modality for osteomyelitis, garnering considerable attention for the potential to overcome antibiotic resistance. This review summarizes the epidemiological characteristics, current treatment approaches, and pathogenic mechanisms of osteomyelitis, and comprehensively examines advances in ROS nanotechnologies for osteomyelitis treatment. In addition, the technical advantages and limitations of major ROS-based strategies, including photodynamic therapy (PDT), sonodynamic therapy (SDT), chemodynamic therapy (CDT), and microwave dynamic therapy (MWDT), are systematically discussed to provide guidance for further optimization of ROS-mediated strategies. Furthermore, the therapeutic potential of these strategies in antimicrobial activity, promotion of tissue repair, and immune regulation is analyzed, offering theoretical support for the integration of ROS-based strategies with existing treatment modalities for improved management of osteomyelitis.

Indexed as

NanotechnologyOsteomyelitisReactive Oxygen SpeciesAnimalsAnti-Bacterial AgentsHumansPhotochemotherapyAnti-Bacterial AgentsReactive Oxygen Speciesnanomaterialsnanotechnologyosteomyelitisreactive oxygen species

Identifiers

PMID41799213
PMCPMC12964132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.